摘要
目的:分析替格瑞洛在心内科冠心病(CHD)住院患者中的应用情况。方法:对2019年11月—2021年12月我院收治的140例CHD患者的一般资料进行回顾性分析。采用本院自制的调查问卷收集患者的药物使用情况(药品名称、种类、用量、用药时间)以及住院期间不良发应发生情况,对替格瑞洛用药合理性进行评价和分析。结果:140例心内科CHD住院患者中,适应证均符合相关指南的推荐;联合使用他汀类药物115例(82.14%)、联合使用抗糖尿病药物72例(51.42%)、联合使用质子泵抑制剂89例(63.57%),以及联合使用活血化瘀类中成药、β受体阻断剂、钙通道阻滞剂、增加出血倾向的药物和CYP3A4强诱导剂分别为85例、96例、1例、1例,占比为60.71%、68.57%、0.71%、0.71%;不良反应发生率为35.00%;单因素分析结果显示,出血者联合使用活血化瘀类中成药比例明显高于未出血者(P<0.05)。结论:替格瑞洛在心内科CHD住院患者临床用药的过程中,多重用药的情况较为常见,且和活血化瘀类中成药联合使用极易出现出血等不良反应,在用药期间应加强对患者的监测,提高用药安全性。
Objective:To analyze the application rationality of ticagrelor in hospitalized patients with coronary heart disease(CHD)in cardiology department.Methods:The general data of 140 patients with CHD admitted to our hospital from November 2019 to December 2021 were retrospectively analyzed.The self-made questionnaire was used to collect the drug use(including drug name,type,dosage,medication time)and adverse events during hospitalization,and the rationality of ticagrelor was evaluated and analyzed.Results:In 140 hospitalized patients with coronary heart disease in cardiology department,all indications meet the recommendation of relevant guidelines.Combined use of statins in 115 cases(82.14%),combined use of antidiabetic drugs in 72 cases(51.42%),combined use of proton pump inhibitors in 89 cases(63.57%)and combined use of Chinese patent medicines for promoting blood circulation and removing blood stasis,beta blockers,calcium channel blockers,drugs to increase bleeding tendency and CYP3A4 strong inducers were 85 cases,96 cases,1 case,1 case,accounting for 60.71%,68.57%,0.71%,0.71%.The incidence of adverse reactions was 35.00%,The results of single factor analysis showed that the proportion of combined use of Chinese patent medicine for promoting blood circulation and removing blood stasis in patients with bleeding was significantly higher than that in patients without bleeding(P<0.05).Conclusion:In the process of clinical use of ticagrelor in hospitalized patients with CHD in cardiology department,multidrug use is more common,and combined with traditional Chinese medicine for promoting blood circulation and removing blood stasis,it is extremely prone to bleeding and other adverse reactions.During medication,monitoring of patients should be strengthened to improve medication safety.
作者
刘金良
吴伟
汪俊军
LIU Jinliang;WU Wei;WANG Junjun(Department of Cardiology,Wuhan Xinzhou District People's Hospital,Wuhan430400,Hubei,China;Department of Splanchnic Vascular Surgery,the Central Hospital of Wuhan,Wuhan 430014,Hubei,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第8期1043-1046,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
基金
湖北省卫生健康委员会科研项目(编号:WJ2019H374)。
关键词
冠心病
替格瑞洛
合理用药
不良反应
Coronary heart disease
Ticagrelor
Rational therapy
Adverse reaction
